Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
The newly built complex of RRIUM, which will be under CCRUM, the apex government organization for research in Unani Medicine
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
